Hoang C. B. Nguyen

Hoang C. B. Nguyen

Auto-generated profile, based on publicly available information

Hoang C. B. Nguyen

Department of Surgery/Otolaryngology, Brigham and Women's Hospital, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Science
Verified
Journal Article
Closed access
PDF file
LFLisa Fish
Lisa Fish
MKMatvei Khoroshkin
Matvei Khoroshkin
ANAlbertas Navickas
Albertas Navickas
KGKristle Garcia
Kristle Garcia
BCBruce Culbertson
Bruce Culbertson
HGHani Goodarzi
Hani Goodarzi
Characterizing a cancer spliceosome: Cells undergo many genomic changes as they progress toward metastatic cancer. One aspect of this change is to RNA expression and splicing isoforms, but how these differences affect tumor progression is not well characterized. Fish et al. developed a computational framework called pyTEISER that identifies structural cis-regulatory elements that control diverse types of RNA regulation. Applying pyTEISER to models of breast cancer metastasis, they discovered an RNA short-stem-loop element that forms a “structural splicing enhancer” that acts in cis to regulate alternative splicing of RNA transcripts. One of these interactions encompasses the RNA-binding protein SNRPA1 and results in alternative exon inclusion that affects metastatic capacity in xenograft models. Thus, RNA element binding may play a role in splicing regulation and is potentially an important component of the cis-splicing code. Science , this issue p. eabc7531

29 October 2021 in Science Advances
Verified
Journal Article
Open access
MAMarine Adlanmerini
Marine Adlanmerini
BKBrianna M. Krusen
Brianna M. Krusen
HNHoang C. B. Nguyen
Hoang C. B. Nguyen
CTClare W. Teng
Clare W. Teng
LWLauren Nicole Woodie
Lauren Nicole Woodie
MLMitchell Avery Lazar
Mitchell Avery Lazar
Loss of SCN REV-ERBs alters oscillator period but does not render the clock arrhythmic.

19 February 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SSShin Saito
Shin Saito
MKMichihisa Kono
Michihisa Kono
HNHoang C.B. Nguyen
Hoang C.B. Nguyen
AEAnn Marie Egloff
Ann Marie Egloff
CMCameron Messier
Cameron Messier
RURavindra Uppaluri
Ravindra Uppaluri
Purpose: Neoadjuvant anti-PD1 (aPD1) therapies are being explored in surgically resectable head and neck squamous cell carcinoma (HNSCC). Encouraging responses have been observed, but further insights into the mechanisms underlying resistance and approaches to improve responses are needed. Experimental Design: We integrated data from syngeneic mouse oral carcinoma (MOC) models and neoadjuvant pembrolizumab HNSCC patient tumor RNA-sequencing data to explore the mechanism of aPD1 resistance. Tumors and tumor-draining lymph nodes (DLN) from MOC models were analyzed for antigen-specific priming. CCL5 expression was enforced in an aPD1-resistant model. Results: An aPD1-resistant mouse model showed poor priming in the tumor DLN due to type 1 conventional dendritic cell (cDC1) dysfunction, which correlated with exhausted and poorly responsive antigen-specific T cells. Tumor microenvironment analysis also showed decreased cDC1 in aPD1-resistant tumors compared with sensitive tumors. Following neoadjuvant aPD1 therapy, pathologic responses in patients also positively correlated with baseline transcriptomic cDC1 signatures. In an aPD1-resistant model, intratumoral cDC1 vaccine was sufficient to restore aPD1 response by enhancing T-cell infiltration and increasing antigen-specific responses with improved tumor control. Mechanistically, CCL5 expression significantly correlated with neoadjuvant aPD1 response and enforced expression of CCL5 in an aPD1-resistant model, enhanced cDC1 tumor infiltration, restored antigen-specific responses, and recovered sensitivity to aPD1 treatment. Conclusions: These data highlight the contribution of tumor-infiltrating cDC1 in HNSCC aPD1 response and approaches to enhance cDC1 infiltration and function that may circumvent aPD1 resistance in patients with HNSCC.

1 May 2024
Verified
Other
Open access
SSShin Saito
Shin Saito
MKMichihisa Kono
Michihisa Kono
HNHoang C.B. Nguyen
Hoang C.B. Nguyen
AEAnn Marie Egloff
Ann Marie Egloff
CMCameron Messier
Cameron Messier
RURavindra Uppaluri
Ravindra Uppaluri
Purpose:Neoadjuvant anti-PD1 (aPD1) therapies are being explored in surgically resectable head and neck squamous cell carcinoma (HNSCC). Encouraging responses have been observed, but further insights into the mechanisms underlying resistance and approaches to improve responses are needed.Experimental Design:We integrated data from syngeneic mouse oral carcinoma (MOC) models and neoadjuvant pembrolizumab HNSCC patient tumor RNA-sequencing data to explore the mechanism of aPD1 resistance. Tumors and tumor-draining lymph nodes (DLN) from MOC models were analyzed for antigen-specific priming. CCL5 expression was enforced in an aPD1-resistant model.Results:An aPD1-resistant mouse model showed poor priming in the tumor DLN due to type 1 conventional dendritic cell (cDC1) dysfunction, which correlated with exhausted and poorly responsive antigen-specific T cells. Tumor microenvironment analysis also showed decreased cDC1 in aPD1-resistant tumors compared with sensitive tumors. Following neoadjuvant aPD1 therapy, pathologic responses in patients also positively correlated with baseline transcriptomic cDC1 signatures. In an aPD1-resistant model, intratumoral cDC1 vaccine was sufficient to restore aPD1 response by enhancing T-cell infiltration and increasing antigen-specific responses with improved tumor control. Mechanistically, CCL5 expression significantly correlated with neoadjuvant aPD1 response and enforced expression of CCL5 in an aPD1-resistant model, enhanced cDC1 tumor infiltration, restored antigen-specific responses, and recovered sensitivity to aPD1 treatment.Conclusions:These data highlight the contribution of tumor-infiltrating cDC1 in HNSCC aPD1 response and approaches to enhance cDC1 infiltration and function that may circumvent aPD1 resistance in patients with HNSCC.

1 May 2024
Verified
Other
Open access
PDF file
SSShin Saito
Shin Saito
MKMichihisa Kono
Michihisa Kono
HNHoang C.B. Nguyen
Hoang C.B. Nguyen
AEAnn Marie Egloff
Ann Marie Egloff
CMCameron Messier
Cameron Messier
RURavindra Uppaluri
Ravindra Uppaluri
Figure S5 A, B. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 tumors harvested on day 16 post tumor inoculation. Number of cells per tumor mg are shown. (n=6 for esc1_Ctrl, n=8 for esc1_CCL5, representative data of two independent experiments.) C. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 DLN harvested on day 16 post tumor inoculation. (Left panel, n=12 for Ctrl, n=14 for esc1_CCL5, pooled data from two independent experiments. Right panel, n=18 for Ctrl, n=20 for esc1_CCL5. Pooled data from three independent experiments.) D, E. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 DLN harvested on day 16 post tumor inoculation. (n= 6 for Ctrl, n=8 for CCL5, representative data of two independent experiments.) F. Total cells (5*105cells/well) isolated from MOC1esc1_Ctrl or MOC1esc1_CCL5 DLNs were stimulated with indicated peptides for 48 hours and evaluated by IFN-γ ELISA. PC; (positive control (PMA + ionomycin)), NC; negative control (no peptides). (Left panel, n=8. Right panel, n=3, representative data of two independent experiments.) G. Flow cytometric analysis of MOC2_Ctrl and MOC2_CCL5 tumors harvested on day 10 post tumor inoculation. (n=8.)

1 May 2024
Verified
Other
Open access
PDF file
SSShin Saito
Shin Saito
MKMichihisa Kono
Michihisa Kono
HNHoang C.B. Nguyen
Hoang C.B. Nguyen
AEAnn Marie Egloff
Ann Marie Egloff
CMCameron Messier
Cameron Messier
RURavindra Uppaluri
Ravindra Uppaluri
Figure S4. A. Heatmap of CXC chemokines ligands (CXCL) based on pretreatment bulk RNA-seq data between responders and non-responders. B. CCL5 expression in each MOC model cultured media with or without IFN-γ stimulation (100U/ml for 48 hours) were analyzed by CCL5-ELISA. n=2-3. C. p value and r squared value calculated from Pearson correlation coefficient of cDC score and chemokine RNA expression are plotted. Broken line represents a p value of 0.05. D. Number of Xcr1+ DCs migrated using the migration assay described in Methods. E. Distribution plots showing cumulative expression levels of CCL5 in various immune subtypes other than CD8+ T cells, based on scRNA-seq of HNSCC patients prior to pembrolizumab. Left panel responders, right panel non-responders. F, G. Comparison of CCL5 expression in bulk RNA-seq data from pre and post treatment samples in responders (F) and non-responders (G), shown as z-score. n=6. H. Violin plot showing CCL5 expression level in human dendritic cells between responders pre- and post-treatment based on scRNA-seq data